BTIG Keeps Their Buy Rating on Vaxcyte (PCVX)
BTIG analyst Thomas Shrader has maintained a Buy rating on Vaxcyte (PCVX) with a price target of $85.00. The overall analyst consensus for Vaxcyte is a Strong Buy, with an average price target of $90.33. Shrader, who focuses on the Healthcare sector, has an average return of 2.6% and a 38.40% success rate on his stock recommendations.
In a report released today, Thomas Shrader from BTIG maintained a Buy rating on Vaxcyte, with a price target of $85.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shrader covers the Healthcare sector, focusing on stocks such as Stoke Therapeutics, Harrow Health, and Gain Therapeutics. According to TipRanks, Shrader has an average return of 2.6% and a 38.40% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vaxcyte with a $90.33 average price target.
